Archive for March, 2007
Viagra saves babies
Lewis Goodfellow, born 16 weeks early, is making excellent progress after being given the drug, also called Sildenafil, to help open blood vessels in his under-developed lungs.
Erin Cottington, on the other hand, is doing well after taking one of the blue pills every day to help keep her blood pressure down.
Lewis, one of the first babies to be given the drug at the Royal Victoria Infirmarys special baby care unit in Newcastle, was born premature, with seriously under-developed lungs.
When he was three weeks old, he needed open-heart surgery to correct a faulty valve. But doctors became increasingly worried about his lungs. Despite being given maximum supplies of oxygen, he still struggled to get it into his blood, reported the Daily Mail.
As a last resort the doctors tried Viagra through a drip and he started to improve.
Now after five months in hospital, Lewis is back at home with his parents. And he is even starting to smile.
Erin Cottington was first given Viagra when she was a few days old to help her overcome life-threatening circulatory problems caused by her under-developed heart and lungs.
Erin was born with her intestines and bowels pushed into her chest cavity, crushing her heart and right lung.
Artificial blood was pumped into her lungs to help increase their capacity. She was given Viagra to open up her blood vessels and improve the flow.
Altogether, Erin had had eight operations, including open-heart surgery, before she was three months old.
After more than 10 months in hospital, Erin returned home to Blackley, Manchester, where she is developing like a normal child.
Source : Thestar
Researchers Identify Predictors of Sexual Dysfunction in Older Men With Prostate Cancer: Presented at EAU
Higher age, body mass index (BMI) and International Prostatic Symptoms Score (IPSS) have been identified as being significantly associated with sexual dysfunction in a large population of men at high risk of developing prostate cancer.
Furthermore, researchers say, there is evidence of an association between erectile dysfunction and prostatic inflammation in this patient population.
Principal investigator Claus G. Roehrborn, MD, professor and chairman, department of urology, University of Texas Southwestern Medical Centre, Dallas, United States, presented the findings from an analysis of the baseline data from a placebo-controlled, phase 3 Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study here at the 22nd Annual Congress European Association of Urology (EAU).
“The question here was: does inflammation at baseline predict the presence or absence of erectile dysfunction, decreased libido or level of sexual activity?” he said in a poster session on March 22nd.
Eligibility criteria for the REDUCE prostate cancer prevention trial included age 50 to 75 years, serum prostate-specific antigen (PSA) level between 2.5 ng/mL and 10 ng/mL for those 50 to 60 years of age or between 3.0 ng/mL and 10 ng/mL for those who were older than 60 years. Patients also were required to have had a negative prostate biopsy in the 6 months prior to enrolment.
The main exclusion criteria included a prostate volume greater than 80 mL, and IPSS score of 25 or greater (or 20 or greater if already on alpha-blocker therapy for benign prostatic hyperplasia), concurrent use (or within the previous 12 months) of a 5 alpha-reductase inhibitor, and acute prostatitis or acute bacterial prostatitis within the previous 6 months.
Source : Docguide